Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.42 USD
Change Today 0.00 / 0.00%
Volume 4.6K
As of 8:10 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

marina biotech inc (MRNA) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - $1.30
52 Week Low
07/30/15 - $0.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MARINA BIOTECH INC (MRNA)

Related News

No related news articles were found.

marina biotech inc (MRNA) Related Businessweek News

No Related Businessweek News Found

marina biotech inc (MRNA) Details

Marina Biotech, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of nucleic acid-based therapies to treat orphan diseases. The company’s therapies include small interfering RNA, microRNA (miRNA) mimics, and antagomirs, as well as antisense compounds, including messengerRNA therapeutics. Its pipeline comprise CEQ508 that is in clinical program for the treatment of Familial Adenomatous Polyposis, a precancerous syndrome; and preclinical programs in type 1 myotonic dystrophy and Duchenne’s muscular dystrophy. The company also has a strategic alliance with Rosetta Genomics, Ltd. to identify and develop miRNA -based products to diagnose and treat various neuromuscular diseases and dystrophies; and with Avecia Nitto Denko to develop, supply, and commercialize various oligonucleotides constructs using company’s conformationally restricted nucleotide technology. It has licensing agreements with Mirna Therapeutics, Inc.; ProNAi Therapeutics, Inc.; Monsanto Company; MiNA Therapeutics, Ltd.; Novartis Institutes for Biomedical Research, Inc.; Protiva Biotherapeutics Inc.; and Arcturus. The company was formerly known as MDRNA, Inc. and changed its name to Marina Biotech, Inc. in July 2010. Marina Biotech, Inc. was founded in 1983 and is based in Bothell, Washington.

1 Employees
Last Reported Date: 04/7/15
Founded in 1983

marina biotech inc (MRNA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $288.1K
Interim Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

marina biotech inc (MRNA) Key Developments

Marina Biotech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 11:00 AM

Marina Biotech, Inc. Presents at BIO International Convention 2015, Jun-16-2015 11:00 AM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: J. Michael French, Chairman, Chief Executive Officer and President.

Marina Biotech, Inc. Enters into an Amendment No. 2 License Agreement; Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

On May 11, 2015, Marina Biotech, Inc. entered into an Amendment No. 2 to that certain License Agreement effective as of December 22, 2011 by and between Mirna Therapeutics, Inc. and the company. Pursuant to Amendment No. 2, Mirna agreed to make a pre-payment to the Company in the amount of $400,000 in full and complete satisfaction of the milestone payment that would otherwise have been payable to the company upon the date the first patient is dosed in the first Phase 2 trial for a licensed product containing or incorporating Mirna's proprietary compound miR-34. The payment was received by the company on May 12, 2015. The company reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. Loss from operations was $1,315,000 against $563,000 a year ago. Net income applicable to common stockholders was $414,000 or $0.04 per basic share against loss of $9,078,000 or $0.70 per basic and diluted share a year ago. The reduced loss in the current quarter is due to a gain related to the fair value of price adjustable warrants, which was partially offset by an increase in operating expenses. Net cash used in operating activities was $662,000 against $1,065,000 a year ago.

Marina Biotech, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Marina Biotech, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company’s license and other revenue was $500,000 against $2,115,000 a year ago. Loss from operations was $3,520,000 against $365,000 a year ago. Loss before income tax was $6,477,000 against $1,610,000 a year ago. Net loss was $6,477,000 or $0.26 per basic and diluted share against $1,571,000 or $0.09 per basic and diluted share a year ago. Net cash used in operating activities was $4,779,000 against net cash from operating activities was $285,000 a year ago. The change in net loss was due primarily to changes in the fair value of certain liabilities and derivatives, changes in other income and expenses related to debt extinguishment accounting in 2013, and increased operating expenses related to 2014 resumption of business operations.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRNA:US $0.42 USD 0.00

MRNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.97 AUD +0.095
Galena Biopharma Inc $1.63 USD 0.00
Regulus Therapeutics Inc $7.77 USD -0.22
Silence Therapeutics PLC 270.00 GBp +3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MRNA Industry Range
Price/Earnings 1.3x
Price/Sales 21.5x
Price/Book NM Not Meaningful
Price/Cash Flow 3.6x
TEV/Sales 19.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MARINA BIOTECH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at